Search / 148 results found

from
to

MONDAY, Jan. 24, 2022 (HealthDay News) -- For health care workers who received a priming dose of the Ad26.COV2.S vaccine, Ad26.COV2.S and mRNA boosters are immunogenic, with the strongest responses after boosting with an mRNA-based vaccine, according to a study published online Jan. 19 in the New England Journal of Medicine.

FRIDAY, Jan. 21, 2022 (HealthDay News) -- Vaccine effectiveness against symptomatic COVID-19 decreases by 20 weeks after the second dose of BNT162b2 or CHAdOx1-S, but limited waning is seen against COVID-19-related hospitalization and death, according to a study published online Jan. 12 in the New England Journal of Medicine.

FRIDAY, Jan. 21, 2022 (HealthDay News) -- The risk of hospitalization for COVID-19 among older Americans is far higher for those who are unvaccinated than for those who are fully vaccinated and have had a booster shot, new government data shows.

  • Updated

THURSDAY, Jan. 20, 2022 (HealthDay News) -- Recommendations have been updated for use of the recombinant zoster vaccine (RZV) for prevention of herpes zoster and related complications among immunocompromised adults aged 19 years and older; the recommendations are available in the Jan. 21 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

  • Updated

THURSDAY, Jan. 20, 2022 (HealthDay News) -- A fourth dose of an mRNA-based anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine may increase antispike immunoglobulin (Ig)G titers in kidney transplant recipients, according to a research letter published online Jan. 11 in the Annals of Internal Medicine.

  • Updated

WEDNESDAY, Jan. 19, 2022 (HealthDay News) -- Two doses of the BNT162b2 vaccine are highly effective against COVID-19-related hospitalization and critical disease in adolescents aged 12 to 18 years, according to a study published online Jan. 12 in the New England Journal of Medicine.